1. Academic Validation
  2. Structural basis for small molecule targeting of Doublecortin Like Kinase 1 with DCLK1-IN-1

Structural basis for small molecule targeting of Doublecortin Like Kinase 1 with DCLK1-IN-1

  • Commun Biol. 2021 Sep 20;4(1):1105. doi: 10.1038/s42003-021-02631-y.
Onisha Patel 1 2 Michael J Roy 3 4 Ashleigh Kropp 3 4 Joshua M Hardy 3 4 Weiwen Dai 3 4 Isabelle S Lucet 5 6
Affiliations

Affiliations

  • 1 The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia. [email protected].
  • 2 Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia. [email protected].
  • 3 The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • 4 Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia.
  • 5 The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia. [email protected].
  • 6 Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia. [email protected].
Abstract

Doublecortin-like kinase 1 (DCLK1) is an understudied bi-functional kinase with a proven role in tumour growth and development. However, the presence of tissue-specific spliced DCLK1 isoforms with distinct biological functions have challenged the development of effective strategies to understand the role of DCLK1 in oncogenesis. Recently, DCLK1-IN-1 was reported as a highly selective DCLK1 inhibitor, a powerful tool to dissect DCLK1 biological functions. Here, we report the crystal structures of DCLK1 kinase domain in complex with DCLK1-IN-1 and its precursors. Combined, our data rationalises the structure-activity relationship that informed the development of DCLK1-IN-1 and provides the basis for the high selectivity of DCLK1-IN-1, with DCLK1-IN-1 inducing a drastic conformational change of the ATP binding site. We demonstrate that DCLK1-IN-1 binds DCLK1 long isoforms but does not prevent DCLK1's Microtubule-Associated Protein (MAP) function. Together, our work provides an invaluable structural platform to further the design of isoform-specific DCLK1 modulators for therapeutic intervention.

Figures